CRDF
CRDF
NASDAQ · Biotechnology

Cardiff Oncology Inc

$0.80
+0.04 (+5.30%)
As of Nov 14, 2:26 AM ET ·
Financial Highlights (FY 2026)
Revenue
634.9K
Net Income
-48,940,375
Gross Margin
100.0%
Profit Margin
-7,732.0%
Rev Growth
+15.0%
D/E Ratio
—
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin 100.0% 100.0% 56.1% 56.1%
Operating Margin -8,256.3% -7,430.7% -18.4% -15.5%
Profit Margin -7,732.0% -7,345.4% -21.6% -17.5%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 634.9K 552.2K 16.05M 19.98M
Gross Profit 634.9K 552.2K 9.01M 11.22M
Operating Income -52,422,678 -41,030,011 -2,950,777 -3,087,601
Net Income -48,940,375 -38,304,493 -3,462,613 -3,502,482
Gross Margin 100.0% 100.0% 56.1% 56.1%
Operating Margin -8,256.3% -7,430.7% -18.4% -15.5%
Profit Margin -7,732.0% -7,345.4% -21.6% -17.5%
Rev Growth +15.0% +15.0% +0.8% +4.1%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 0 0 38.47M 47.77M
Total Equity — — 57.67M 59.42M
D/E Ratio — — 0.67 0.80
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA -51,865,382 -42,849,041 -3,307,317 -3,822,507
Free Cash Flow — — -2,137,974 -3,204,130